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The C-type lectin dendritic cell (DC)-specific intercellular adhesion molecule 3-grabbing nonintegrin (DC-
SIGN) is the major receptor on DCs for mycobacteria of the Mycobacterium tuberculosis complex. Recently, we
have shown that although the mannose caps of the mycobacterial surface glycolipid lipoarabinomannan
(ManLAM) are essential for the binding to DC-SIGN, genetic removal of these caps did not diminish the
interaction of whole mycobacteria with DC-SIGN and DCs. Here we investigated the role of the structurally
related glycolipids phosphatidylinositol mannosides (PIMs) as possible ligands for DC-SIGN. In a binding
assay with both synthetic and natural PIMs, DC-SIGN exhibited a high affinity for hexamannosylated PIM6,
which contains terminal (132)-linked mannosyl residues identical to the mannose cap on ManLAM, but not
for di- and tetramannosylated PIM2 and PIM4, respectively. To determine the role of PIM6 in the binding of
whole mycobacteria to DC-SIGN, a mutant strain of M. bovis bacillus Calmette-Gue´rin deficient in the
production of PIM6 (pimE) was created, as well as a double knockout deficient in the production of both PIM6
and the mannose caps on LAM (pimE capA). Compared to the wild-type strain, both mutant strains bound
similarly well to DC-SIGN and DCs. Furthermore, the wild-type and mutant strains induced comparable levels
of interleukin-10 and interleukin-12p40 when used to stimulate DCs. Hence, we conclude that, like ManLAM,
PIM6 represents a bona fide DC-SIGN ligand but that other, as-yet-unknown, ligands dominate in the
interaction between mycobacteria and DCs.
Tuberculosis (TB), caused by the bacterium Mycobacterium
tuberculosis, is a major cause of death world wide and claims
approximately 1.7 million lives each year (74). Currently, it is
estimated that about one-third of the total world population is
latently infected and this number continues to rise. Besides
macrophages, which are the primary target for infection by
mycobacteria (21), dendritic cells (DCs) are pivotal in deter-
mining the nature of the antimycobacterial response (15, 35,
38). Importantly, mycobacteria, including the vaccine strain M.
bovis bacillus Calmette-Gue´rin (BCG), are able to suppress
the immune response by interfering with the normal function
of DCs (23, 73). Induction of the immunosuppressive cytokine
interleukin-10 (IL-10) has a negative effect on the production
of the proinflammatory cytokine IL-12 and inhibits a Th1-
biased response which is necessary for mycobacterial clearance
(14, 45). Responsible for at least part of this immune modu-
lation is the binding of mycobacteria to the C-type lectin DC-
specific intercellular adhesion molecule 3-grabbing noninte-
grin (DC-SIGN [CD209]) (26, 69). This lectin has been shown
to be the major mycobacterial receptor expressed by DCs (6,
66). DC-SIGN signaling enhances the transcription of the
IL-10 gene upon Toll-like receptor (TLR) signaling (30). In
addition, the level of DC-SIGN expression on host cells has
been related to susceptibility to and the pathogenicity of my-
cobacterial infections (7, 51, 70).
The cell wall components on mycobacteria that dominate
the interaction of mycobacteria with DC-SIGN are currently
unknown. Several ligands have been studied so far: the man-
nosylated 19-kDa and 45-kDa antigens, mannose-capped li-
poarabinomannan (ManLAM), arabinomannan (AM), lipo-
mannan (LM), and phosphatidylinositol mannosides (PIMs)
(27, 46, 59, 67). The 19- and 45-kDa glycoproteins were shown
to have an inhibitory effect on mycobacterial binding to DC-
SIGN (59). However, M. tuberculosis mutants deficient in these
glycoproteins bound DC-SIGN as well as the wild-type strain
did (59). For a long time, mycobacterial binding to DC-SIGN
was thought to be mediated by ManLAM. Several studies
showed that ManLAM, in contrast to AraLAM, which is Man-
LAM devoid of mannose caps, strongly binds to DC-SIGN and
induces the production of IL-10 (27, 46). Yet, these studies
were all performed with purified compounds. Strikingly, mu-
tation of capA (Rv1635c), i.e., the gene responsible for the
mannose capping of LAM (16), did not attenuate M. bovis
BCG in in vitro and in vivo infection models (5). In addition,
there was no significant reduction in binding of the mutant
strain to DC-SIGN, compared to that of the wild-type strain
(5). Therefore, additional DC-SIGN ligands must be present.
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The third group of ligands, the PIMs, were also shown to be
able to bind to DC-SIGN (67). However, as for ManLAM,
functional studies with live bacteria assessing the role of PIMs
in the Mycobacterium–DC-SIGN interaction have yet to be
conducted. PIMs are structurally related to LAM (for a review,
see references 13 and 52). Like LAM, PIMs contain a manno-
sylated glycosylphosphatidylinositol (GPI) anchor, which can
be further acylated at two positions (Fig. 1). The number of
mannosyl residues can range from one to six, as is denoted by
the subscript to PIM (PIM1 to PIM6), with tri- and tetra-
acylated PIM2 and PIM6 as the predominant species (48).
LAM and PIMs share the initial steps of their biosynthesis
(40), with PIM4 as the assumed branching point (11, 43). It is
noteworthy that the (132)-linkage, which is only present
between the terminal mannosyl residues of the polar PIMs, i.e.,
PIM5 and PIM6, is identical to the linkage between the termi-
nal mannosyl residues in the mannose caps of LAM (Fig. 1).
Previous studies have shown that DC-SIGN recognizes
(132)-linked dimannosyl and trimannosyl structures, with
the affinity increasing with length (20, 42, 61). Furthermore,
PIMs are present in the outermost layer of the mycobacterial
cell envelope (54), where they function as adhesins for myco-
bacterial binding to both macrophages and nonphagocytic cells
(36, 47, 71). These observations suggest that PIMs may be
involved in the interaction between mycobacteria and DC-
SIGN.
In this study, we investigated the role of PIMs in the inter-
action between mycobacteria and DC-SIGN. We first deter-
mined the ability of DC-SIGN to interact with distinct species
of PIMs by using both natural and synthetic PIMs (natPIMs
and synPIMs, respectively). We found that DC-SIGN exhibited
a high affinity for polar PIM6, yet binding to the apolar, less
mannosylated PIMs, i.e., PIM2 and PIM4, could not be ob-
served. The next step was to further clarify the role of PIMs in
the binding of mycobacteria to DC-SIGN. The enzyme cata-
lyzing the transfer of the fifth mannose to PIM4 to produce
PIM5 is PimE (Rv1159) (49); thus, a mutant strain of M. bovis
BCG (pimE) that expresses PIM2 and PIM4 but not PIM6
was created. To overcome the possibility of redundancy be-
tween ligands for DC-SIGN, we also constructed a double
mutant devoid of both PIM6 and the mannose caps on LAM
(pimE capA). Unexpectedly, both mutant strains bound as
well to both DC-SIGN and DCs as did the wild-type strain.
Furthermore, when the wild-type and mutant strains were used
to stimulate DCs, we did not find indications of a different
skewing (IL-12p40/IL-10 ratio) of the immune response be-
tween the strains. Hence, we conclude that although PIM6 is a
ligand for DC-SIGN, its role in the interaction between myco-
bacteria and DC-SIGN, like that of the mannose caps on
LAM, is limited. Binding of the mutant strains to DC-SIGN
and DCs could still be blocked by mannan and antibodies
against DC-SIGN, suggesting that other, as-yet-unknown, li-
gands for DC-SIGN must be present on the mycobacterial cell
surface.
MATERIALS AND METHODS
Bacterial strains and growth conditions.M. bovis BCG strain Copenhagen (8)
was grown in Middlebrook 7H9 broth (Difco) with 10% Middlebrook albumin-
dextrose-catalase enrichment (BBL) and 0.05% Tween 80 or on Middlebrook
7H10 agar (Difco) with 10% Middlebrook oleic acid-albumin-dextrose-catalase
enrichment (BBL) at 37°C. Escherichia coli strain DH5 (32) was grown on
Luria-Bertani agar at 37°C. The concentrations of antibiotics used were 25 g
ml1 kanamycin and 50 and 100 g ml1 hygromycin for M. bovis BCG and E.
coli, respectively.
Construction of M. bovis BCG mutant strains. An unmarked deletion muta-
tion in pimE (BCG_1220, homolog of Rv1159) was constructed in both wild-type
M. bovis BCG and the M. bovis BCG capA (BCG_1673c, homolog of Rv1635c)
mutant, which produces LAM devoid of mannose caps (5), by using a two-step
strategy involving vectors pGOAL19 and p2NIL (57). First, two fragments har-
boring the up- and downstream regions of pimE, respectively, were amplified by
PCR from M. bovis BCG genomic DNA with primer set BCG_1220-LF (5-CT
GGGCAAACTATTGGTGGT-3) and BCG_1220-LR (5-CAGGTGATGATC
CCGTCTTT-3), primer set BCG_1220-RF (5-CGATCGAGGGGTACATGA
AG-3) and BCG_1220-RR (5-CAGATAGGTCCAGGCGAGTC-3), and Pfu
DNA polymerase (Fermentas). The temperature program was as follows: 94°C
for 5 min; 30 cycles of 30 s at 96°C, 30 s at 56.5°C, and 2 min at 72°C; followed
by 7 min at 72°C and subsequent cooling to 4°C. PCR products were cloned
separately into pCRII-TOPO according to the manufacturer’s instructions (In-
vitrogen). They were cut out by using the EcoRI sites of pCRII-TOPO and
ligated to each other in order to obtain the knockout pimE construct in which 771
bp of the gene were deleted. Constructs were checked for the correct orientation
of the two fragments with primers BCG_1220-LR and BCG_1220-RF and re-
cloned into pCRII-TOPO. A HinDIII/PstI digest from pCRII-TOPO-pimE was
ligated into HinDIII/PstI-digested p2NIL. A hyg-PAg85-lacZ-Phsp60-sacB marker
was cassette cut out from the pGOAL19 plasmid with PacI and subsequently
cloned into the PacI site of p2NIL-pimE to obtain the final plasmid, which was
then electroporated into wild-type and capA mutant M. bovis BCG (56). Se-
lection of mutants was performed as described previously (57). In short, after
single-crossover events, we selected Kanr Hygr Sucs blue colonies which harbor
both wild-type pimE and a pimE gene with a deletion mutation, the hygromycin
and kanamycin resistance genes (hyg and kan, respectively), lacZ, and sacB.
Double-crossover events were induced by selection on plates containing 2%
(wt/vol) sucrose. The colonies obtained (Kans Hygs Sucr) either contained a
wild-type or a mutant copy of pimE. Potential mutants were screened for the
presence or absence of the deletion fragment by PCR with various primer sets.
Complementation of M. bovis BCG mutant strains. The pimE gene was am-
plified from genomic BCG DNA with primers BCG_1220-F-BamHI (5-GGAT
CCGATGGTTGGCATGTCTCT-3) and BCG_1220-R (5-AGGTGGTATCA
CGGAAAACG-3) and Pfu DNA polymerase (Fermentas). The following PCR
program was used: 95°C for 3 min; 35 cycles of 30 s at 94°C, 30 s at 55°C, and 3
min at 72°C; and 7 min at 72°C. The PCR product obtained was cloned into
pCRII-TOPO. This plasmid was digested with BamHI and Eco32I, and the
FIG. 1. Structure of synPIM6. PIM6 consist of a GPI anchor man-
nosylated with six mannosyl residues. natPIMs can be further acylated
at the mannosyl group attached to the C-2 position of the inositol ring
(Ac1 PIMs) and subsequently at the C-3 position of inositol itself (Ac2
PIMs). PIM4 consists of a GPI anchor with four mannosyl residues in
which the three mannosyl residues extending from the C-6 position of
the inositol ring are linked in an (136) configuration. The terminal
mannosyl residue in PIM4 is substituted with two (132)-linked man-
nosyl residues to form PIM6. This part of PIM6 is identical to the
(132)-linked mannosyl residues in the mannose cap on ManLAM.
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fragment was ligated into BamHI/Eco32I-digested pSMT3-eGFP (1, 33). In the
resulting plasmid, pSMT3-pimE, the pimE gene was located behind the heat
shock promoter 60 gene. pSMT3-pimE was isolated from E. coli DH5 cells with
a QIAprep Miniprep kit (Qiagen) and electroporated into M. bovis BCG pimE
as described previously (55). Transformants were selected on hygromycin. For
complementation of the M. bovis BCG pimE capA mutant, pimE was ampli-
fied with primers BCG_1220-F-BamHI and BCG_1220-R-BcuI (5-ACTAGTA
GGTGGTATCACGGAAAA-3) with the following PCR program: 95°C for 5
min; 35 cycles of 30 s at 94°C, 30 s at 58°C, and 3 min at 72°C; and 7 min at 72°C.
The PCR product was cloned into pCRII-TOPO. The BamHI/BcuI digest of this
plasmid was cloned into the BamHI/BcuI site of plasmid pSMT3-capA (5) to
obtain pSMT3-pimE-capA.
MAbs and DC-SIGN-Fc. Murine monoclonal antibodies (MAbs) of the im-
munoglobulin M (IgM) class were used. MAb F30-5 recognizes the carbohydrate
structure (Ara)6 (for its structure, see reference 42) and binds both ManLAM
and AraLAM (5, 41). MAb 55.92.1A1 binds the mannose cap on LAM (5).
F183-24 recognizes (132)-linked mannosyl residues as present in the mannose
cap on ManLAM and PIM6 (41). The DC-SIGN-Fc construct consists of the
extracellular portion of DC-SIGN C terminally fused to a human IgG1-Fc frag-
ment (25). In all experiments involving DC-SIGN-Fc, Tris-buffered saline con-
taining 20 mM Tris, 150 mM NaCl, 1 mM MgCl2, 2 mM CaCl2 (TSM), and 0.5%
bovine serum albumin (Fluka) was used instead of phosphate-buffered saline
(PBS).
PIMs. Synthetic 2,6-(di-O--D-mannopyranosyl)-1-O-(1,2-di-O-palmitoyl-sn-
glycero-3-phosphoryl)-D-myo-inositol (synPIM2) and synthetic 1-O-(1,2-di-O-
hexadecanoyl-sn-glycero-3-phosphoryl)-2-O-(-D-mannopyranosyl)-6-O-[(-D-
mannopyranosyl)-(136)-(-D-mannopyranosyl)-(136)-(-D-mannopyranosyl)]-
D-myo-inositol (synPIM4) were prepared by following methods published
elsewhere (3). A synthetic sample of 1-O-(1,2-di-O-hexadecanoyl-sn-glycero-3-
phosphoryl)-2-O-(-D-mannopyranosyl)-6-O-[(-D-mannopyranosyl)-(132)-(-
D - m a n n o p y r a n o s y l ) - ( 132 ) - ( - D - m a n n o p y r a n o s y l ) - ( 136 ) - ( - D -
mannopyranosyl)-(136)-(-D-mannopyranosyl)]-D-myo-inositol (synPIM6) was
synthesized from the starting material 1-O-allyl-3,4,5-tri-O-benzyl-D-myo-
inositol. Key synthetic steps included the thioglycosylation of 1-O-allyl-2-O-(2-
O-benzoyl-3,4,6-tri-O-benzyl--D-mannopyranosyl)-6-O-(2-O-benzoyl-3,4-di-O-
benzyl--D-mannopyranosyl)-3,4,5-tri-O-benzyl-D-myo-inositol with phenyl (2-O-
benzoyl-3,4,6-tri-O-benzyl--D-mannopyranosyl)-(132)-(3,4,6-tri-O-benzyl--D-
mannopyranosyl)-(132)-(3,4,6-tri-O-benzyl--D-mannopyranosyl)-(136)-2-O-
benzoyl-3,4-di-O-benzyl-1-thio--D-mannopyranoside in 76% yield and
introduction of the diacylglycerol moiety by phosphoramidite coupling method-
ology. synPIM6 analyzed for C77H138O43P; high-resolution mass spectrometry–
electrospray ionization [M-H] found, 1,781.8358. synPIM6 was further charac-
terized by treatment with hydrazine to afford dPIM6; 1H NMR (500 MHz, D2O)
 5.30 (br s, 1H), 5.20 (br s, 1H), 5.13 (br s, 1H), 5.12 (br s, 1H), 5.06 (br s, 1H),
4.91 (br s, 1H), 4.35 (br s, 1H), 4.23 to 3.59 (m, 45H), 3.39 (t, J  9.1 Hz, 1H).
13C NMR (125 MHz, D2O, selected data)  103.1, 102.6, 102.2, 101.6, 100.5, 99.2.
High-resolution mass spectrometry–electrospray ionization [M-H]; calculated
for C45H78O41P, 1,305.3756; found, 1,305.3738.
The natPIMs (natPIM1,2 and natPIM6) were purified from M. tuberculosis
H37Rv and contained a mixture of differently acylated PIMs. The natPIMs were
a gift from Colorado State University.
SDS-PAGE and immunoblotting. M. bovis BCG was grown until mid to late
log phase and disrupted with a Beadbeater (BioSpec). Supernatants were equal-
ized for protein content, as quantified by the bicinchoninic acid protein assay kit
according to the manufacturer’s instructions (Pierce). Cell lysates were subjected
to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
in glycine buffer for immunostaining with MAb F30-5 or 55.92.1A1 or to 12%
SDS-PAGE in Tricine buffer for incubation with MAb F183-24 or DC-SIGN-Fc
(44). After transfer onto a polyvinylidene difluoride membrane (Millipore) (68),
the membrane was incubated in blocking reagents (Boehringer), followed by
incubation with the MAbs. After washing, incubation with peroxidase-labeled
goat-anti-mouse IgM (American Qualex) and 0.5% normal goat serum followed.
Membranes probed with DC-SIGN-Fc were blocked with 1% bovine serum
albumin (Fluka), and goat anti-human IgG-peroxidase (Jackson Laboratories) in
0.5% normal goat serum was used as the secondary antibody (5, 6). Membranes
were developed with a mixture of 4-chloro-1-naphthol (Bio-Rad) and 3,3-
diaminobenzidine.4HCl (Sigma-Aldrich).
DC-SIGN-Fc adhesion assay. synPIMs and natPIMs were used to coat en-
zyme-linked immunosorbent assay (ELISA) plates (Nunc 96-well PolySorp) by
adding methanol-dissolved PIMs (1 or 10 g per well) and overnight evaporation
to dryness at room temperature. Titration of DC-SIGN-Fc (starting from 1.25 g
ml1) was performed with the protocol as described for immunoblotting with
o-phenylenediamine dihydrochloride (Sigma-Aldrich) as the coloring reagent
(27). To verify proper coating, ELISA plates were coated with various concen-
trations of PIMs and probed with MAb HA-1A, which recognizes hydrophobic
structures (34). HA-1A bound to the less mannosylated PIMs as well as to PIM6.
The median staining ratios (measured by absorption at 490 nm) in nine data sets
derived from three independent experiments were 0.9 for synPIM2/synPIM6, 1.1
for synPIM4/synPIM6, and 0.9 for natPIM1,2/natPIM6.
Two-dimensional (2D) thin-layer chromatography (TLC) for polar lipid anal-
ysis. Cells were harvested by centrifugation and washed once with PBS, and
small-scale lipid extraction was performed to afford polar lipids as described
previously (5, 10). The extracts were resuspended in CHCl3-CH3OH (2:1), and
crude lipids were applied to the corners of aluminum-backed TLC plates
(Merck). The plates were developed in solvent system E for polar lipid extracts
(10). TLC was run once in each direction with CHCl3-CH3OH-H2O (60:30:6) in
the first direction and CHCl3-acetic acid-CH3OH-H2O (40:25:3:6) in the second.
Lipids were visualized by staining with -naphthol and brief charring at 100°C
until lipids appeared, which could then be compared to known standards (10).
Cells. Human peripheral blood mononuclear cells were isolated from buffy
coats (Sanquin Blood Bank, Amsterdam, The Netherlands) by centrifugation on
a Ficoll-Paque gradient (GE Healthcare), followed by selection for CD14
monocytes with anti-CD14 MAb-coupled magnetic beads and the Midi-MACS
system (Miltenyi Biotech) (30). Fresh monocytes were cultured in the presence
of IL-4 (500 U ml1) and granulocyte-macrophage colony-stimulating factor
(800 U ml1; PeproTech) to produce immature monocyte-derived DCs
(MoDCs) (62), which were used for further experiments on day 6 after isolation.
MoDCs, Raji cells, and transfected Raji cells expressing DC-SIGN (Raji 
DC-SIGN cells) (24, 75) were cultured in RPMI 1640 medium (Gibco) supple-
mented with 10% fetal calf serum (Gibco), 100 U ml1 penicillin, and 100 g
ml1 streptomycin at 37°C in a 5% CO2 atmosphere.
Binding of DC-SIGN to PIMs and M. bovis BCG as determined by flow
cytometry. synPIMs and natPIMs were used to coat 1.0-m fluorescent beads
(Polysciences no. 17154) by adding 50 g PIMs to 1 ml 0.1 M carbonate-
bicarbonate buffer (pH 9.6) containing 1.4 	 109 beads in presiliconized tubes
(Sigma-Aldrich). After 1 h of rotating at 37°C, beads were collected by centrif-
ugation and incubated for another hour in 1 ml 5% human serum albumin (HSA;
Sigma-Aldrich) in TSM and washed in 0.5% HSA in TSM (65).
M. bovis BCG cultures were grown until mid-log phase, concentrated, and
incubated with 1 mg ml1 fluorescein isothiocyanate (Sigma-Aldrich) for 15 min
at room temperature, after which the suspensions were washed and declumped
by passage through a 5-m filter (Millipore).
Fluorescence of the different bead and mycobacterial suspensions was quan-
tified with a FLUOstar-Galaxy microplate reader (BMG). Beads were added to
human cells at a ratio of 50:1, and mycobacteria were added at a multiplicity of
infection (MOI) of 0.5, 2, or 8. After incubation for 45 min at 37°C in the absence
or presence of 2 mg ml1 mannan (Sigma-Aldrich), the percentage of fluorescent
cells was determined with a FACScan analytic flow cytometer (Becton Dickin-
son) and analyzed with the manufacturer’s software (CellQuest version 3.1f).
Phagocytosis. MoDCs and mycobacteria were cocultured at a MOI of 1 to 2
(in triplicate in each independent experiment) for 3 h at 37°C, after which
amikacin (Sigma) was added to a concentration of 200 g ml1 for 2 h of
incubation at 37°C. The MoDCs were then washed three times in PBS and finally
lysed with 1% Triton X-100 (Sigma) in PBS for 20 min. Serial dilutions of the
inoculum and the released mycobacteria were made in PBS–0.05% Tween 80
and plated on 7H10 agar. CFU were counted after 4 weeks (1).
Cytokine induction. MoDCs and mycobacteria were cocultured for 24 h at
37°C in the absence or presence of 10 ng ml1 lipopolysaccharide (LPS) from
Salmonella enterica serotype Abortusequi (Sigma-Aldrich). IL-10 and IL-12p40
concentrations in supernatants were analyzed with an ELISA against human
IL-10 and IL-12p40 according to the manufacturer’s instructions (BioSource).
Statistical analysis. All values were expressed as means of triplicates 
 stan-
dard deviation. The unpaired Student t test was used to identify differences
between groups. A P value of 0.05 was considered statistically significant.
RESULTS
DC-SIGN has a higher affinity for PIM6 than for less man-
nosylated PIMs. DC-SIGN exhibits a high affinity for (132)-
linked mannosyl residues (42). As (132)-linked mannosyl
residues are present in polar PIMs, i.e., PIM6, but absent in
apolar PIMs, i.e., PIM4, PIM2, and PIM1 (Fig. 1), we set out to
investigate the affinity of DC-SIGN for different species of
PIMs with two independent assays. First, individual PIM com-
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pounds (purified natPIMs and synPIMs) were used to coat
ELISA plates and probed with a DC-SIGN-Fc construct. As
shown in Fig. 2A, DC-SIGN-Fc strongly bound to both syn-
PIM6 and natPIM6 but not to synPIM2, synPIM4, and nat-
PIM1,2 (a mixture of PIM1 and PIM2), suggesting that DC-
SIGN-Fc specifically recognized PIM6. To determine whether
native, membrane-localized DC-SIGN exhibited a similar
specificity, fluorescent polystyrene beads were coated with the
different species of PIMs and assayed for the capacity to bind
to MoDCs (Fig. 2B) and Raji cells expressing DC-SIGN (see
Fig. S1 in the supplemental material). Consistent with the
results for DC-SIGN-Fc, only beads coated with PIM6 (both
natural and synthetic), compared to control beads coated with
HSA, showed significantly increased binding. The interaction
could be blocked by the addition of mannan (Fig. 2B) and by
DC-SIGN-blocking antibody AZN-D1 (see Fig. S2 in the sup-
plemental material), confirming that binding was dependent
on DC-SIGN.
Construction of an M. bovis BCG pimE mutant deficient in
polar PIM production. As demonstrated above, DC-SIGN
specifically bound to PIM6. To study the role of PIM6 in the
interaction between DC-SIGN and whole mycobacteria, our
next goal was to create a mutant strain deficient in the pro-
duction of PIM6. Recently, it was demonstrated that pimE
encodes the mannosyltransferase responsible for the elonga-
tion of PIM4 to PIM5 and that mutation of the gene abolished
the production of polar PIMs (49). Hence, we created a pimE
knockout of M. bovis BCG. As PIM6 may show redundancy
with ManLAM in binding to DC-SIGN, we also constructed a
double knockout deficient in both PIM6 and the mannose caps
on LAM (pimE capA). First, the composition of PIMs in the
cell wall of the wild-type and mutant strains was analyzed by
2D TLC. As shown in Fig. 3, all of the strains produced PIM2,
yet PIM6 was only present in the wild-type strain. In contrast,
the mutant strains accumulated PIM4, which is consistent with
the report on the mutation of the homologous gene in M.
smegmatis mc2155 (49). Next, whole-cell lysates were probed
by SDS-PAGE and immunoblotting with MAb F183-24, which
recognizes PIM6 (A. H. J. Kolk, unpublished data) (Fig. 4,
lower left panel). In the low-molecular-weight part of the blot
(14 kDa), which is the region harboring the PIMs (39, 59),
F183-24 bound to PIMs from wild-type M. bovis BCG and the
complemented strains (Fig. 4, lanes 1 and 6 and lanes 3 and 5,
respectively) but not to PIMs from the pimE and pimE
capA mutant strains (lanes 2 and 4, respectively). As ex-
pected, since the LAM/PIM biosynthesis pathway bifurcates
after PIM4 (11, 43), the mutant strains still produced LAM, as
indicated by the retained interaction with anti-LAM MAb
F30.5 (Fig. 4, upper left panel). M. bovis BCG pimE capA
only produced capless AraLAM, as shown by the lack of stain-
ing with cap-specific MAb 55.92.1A1 (Fig. 4, upper right panel,
lane 4). Compared to wild-type M. bovis BCG, no additional
FIG. 2. Affinity of DC-SIGN(-Fc) for different species of PIMs (the
degree of mannosylation is indicated by subscripts). (A) PIMs were
used to coat ELISA plates; this was followed by titration with DC-
SIGN-Fc. One representative experiment out of five (synPIMs) or
three (natPIMs) is shown. (B) PIMs were used to coat fluorescent
beads and analyzed for binding to MoDCs by flow cytometry. Indicated
are the means of triplicates and the standard deviations. One repre-
sentative experiment out of three (synPIMs) or two (natPIMs) is
shown. This experiment was also repeated five and two times for the
synPIMs and natPIMs, respectively, with Raji  DC-SIGN cells (see
Fig. S1 in the supplemental material). ***, P  0.0005; **, P  0.005;
*, P  0.05 (compared to control HSA-beads).
FIG. 3. 2D TLC lipid profile of wild-type and pimE and pimE capA mutant M. bovis BCG with solvent system E for polar lipid extracts
(10). Ac1 PIM2, Ac1 PIM4, and Ac1 PIM6 are triacylated PIM2, PIM4, and PIM6, respectively; Ac2 PIM2, Ac2 PIM4, and Ac2 PIM6 are tetra-acylated
PIM2, PIM4, and PIM6, respectively.
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alterations of the lipid composition in the mutant strains were
observed (see Fig. S7 in the supplemental material).
Binding of DC-SIGN-Fc to LAM and PIMs from wild-type
M. bovis BCG and the pimE and pimE capA mutant
strains. To evaluate the consequences of the pimE and capA
mutations for the recognition of LAM and PIMs by DC-SIGN-
Fc, whole-cell lysates from the wild-type and mutant strains
were analyzed by Tricine-SDS-PAGE, followed by immuno-
blotting with DC-SIGN-Fc. As shown in Fig. 4 (lower right
panel), DC-SIGN-Fc did not show binding at the position of
PIMs for both the pimE and pimE capA mutant strains
(lanes 2 and 4, respectively). This binding pattern is similar to
the immunostaining with F183-24 (Fig. 4, lower left panel,
lanes 2 and 4, respectively), which confirms the selective affin-
ity of DC-SIGN-Fc for (132)-interlinked mannosyl residues
present in PIM6. Loss of DC-SIGN-Fc binding to LAM with-
out the mannose cap (capA) has been demonstrated in pre-
vious studies (5, 27) and was also observed at the position of
LAM in the cell lysate from M. bovis BCG pimE capA (Fig.
4, lane 4). Hence, in the M. bovis BCG pimE capA mutant,
two ligands for DC-SIGN were absent. Complementation of
the mutant strains restored the binding of DC-SIGN-Fc to
both LAM and the PIMs (Fig. 4, lanes 3 and 5, respectively).
Binding to DC-SIGN and phagocytic uptake of wild-type M.
bovis BCG and the pimE and pimE capA mutant strains.
To determine the effect of the pimE and capA mutations on the
binding of whole mycobacteria to DC-SIGN-expressing cells,
the wild-type and mutant strains were tested for the ability to
bind MoDCs by flow cytometry. As shown in Fig. 5A, all three
strains bound similarly well at all three of the MOIs tested. To
test if a reduction in binding to DC-SIGN was possibly com-
pensated for by other receptors on the MoDCs, the same assay
was performed with Raji cells expressing DC-SIGN. As indi-
cated in Fig. 5B, the M. bovis BCG pimE and pimE capA
mutants showed a cell-binding pattern similar to that of the
wild-type strain. Furthermore, the binding to MoDCs could be
blocked by the addition of mannan (Fig. 5A) and by DC-
SIGN-blocking antibody AZN-D1 (see Fig. S4 in the supple-
mental material), confirming that the interaction of the mutant
strains with MoDCs was still dependent on DC-SIGN. Al-
though variation in binding was observed in some experiments,
binding of the mutant strains was never significantly lower. In
contrast, in three out of six experiments, a 1.5-fold increase in
the binding of the mutant strains could be observed (data not
shown). These data, together with the observation that the
interactions could still be blocked by mannan, suggest that
even in the pimE capA double knockout, additional ligands
for DC-SIGN were present. Next, the wild-type and mutant
strains were assayed for phagocytic uptake by MoDCs after 3 h
of coculturing (see Fig. S5 in the supplemental material). A
high variation in uptake efficiency was observed between the
different donors. Nevertheless, the M. bovis BCG pimE
capA mutant strain showed a consistent increase in phago-
cytic uptake compared to that of the wild-type strain in five of
the six experiments (see Fig. S5 in the supplemental material).
The median of the ratios of the uptake of M. bovis BCG pimE
FIG. 4. SDS-PAGE and immunoblotting. M. bovis BCG cell lysates
were subjected to glycine-SDS-PAGE (upper panels) or Tricine-SDS-
PAGE (lower panels), transferred to polyvinylidene difluoride mem-
brane, and probed with MAbs F30-5 (anti-AraLAM), 55.92.1A1 (anti-
ManLAM), and F183-24 (anti-PIM6) and DC-SIGN-Fc. The position
of LAM on the blot is between 35 and 45 kDa, and that of the PIMs
is below 14 kDa. Lanes 1 and 6, wild-type M. bovis BCG; lane 2, M.
bovis BCG pimE; lane 3, M. bovis BCG pimE complemented with
pSMT3-pimE; lane 4, M. bovis BCG pimE capA; lane 5, M. bovis
BCG pimE capA complemented with pSMT3-pimE-capA.
FIG. 5. Binding assay with (A) MoDCs and (B) Raji cells express-
ing DC-SIGN. Cells were incubated with wild-type M. bovis BCG or
with the pimE and pimE capA mutants at a MOI of 0.5, 2, or 8 for
45 min in the presence or absence of mannan. The percentage of the
cell population binding M. bovis BCG was determined by flow cytom-
etry. Shown are means of triplicates and the standard deviations. For
binding to both MoDCs and RajiDC-SIGN cells, one representative
experiment out of three is shown. See Fig. S3 in the supplemental
material for the control binding assay with wild-type Raji cells. ***,
P 0.0005; **, P 0.005; *, P 0.05 (compared to wild-type M. bovis
BCG at equal MOIs).
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capA to the uptake of wild-type M. bovis BCG was 2.2, which
is in line with the increased binding of the mutant strain that
was observed in the earlier binding studies. The data from the
CFU count of the M. bovis BCG pimE mutant strain were less
consistent. For two donors, the bacterial uptake was increased,
whereas for the third donor it was lower (see Fig. S5 in the
supplemental material). Hence, drawing conclusions for this
mutant strain was not possible.
Wild-type M. bovis BCG and the pimE and pimE capA
mutant strains induce similar cytokine profiles in MoDCs.
DC-SIGN ligation interferes with TLR signaling and enhances
transcription of IL-10 (27, 30). In addition, it has been shown that
purified ManLAM inhibits the production of IL-12 by human
DCs (53). Hence, removal of DC-SIGN ligands may induce
an altered cytokine secretion profile in Mycobacterium-stim-
ulated DCs. To determine the effect of the pimE and capA
mutations on the ability to induce cytokine secretion in
MoDCs, MoDCs (both immature and LPS primed) were stim-
ulated with the wild-type and mutant bacteria, after which the
amounts of secreted IL-10 and IL-12p40 were determined.
Although the Mycobacterium-induced cytokine secretion var-
ied among the five different donors tested, no consistent dif-
ferences within a single donor were observed. Nevertheless, in
some experiments, such as the one shown in Fig. 6, significant
differences at certain MOIs could be observed. In general, the
mutant strains induced more IL-12p40 and IL-10 (see Fig. S9
in the supplemental material). Of note, in all five of the donors
tested, both immature and LPS-primed MoDCs produced IL-
12p40 following stimulation. In contrast, IL-10 secretion was
only observed in LPS-primed MoDCs. Since bioactive IL-12
consists of two subunits, i.e., IL-12p40 and IL-12p35, with the
p40 subunit also being present in other IL-12 family members,
we also determined the amount of secreted IL-12p70. Al-
though a difference in absolute cytokine production was ob-
served, with the amount of secreted IL-12p40 being higher
than that of IL-12p70 by a factor 10 to 100, depending on the
donor, their relative levels of induction were similar (see Fig.
S8 in the supplemental material). The ratios of IL-12p40/IL-10
induced by M. bovis BCG pimE to IL-12p40/IL-10 induced by
wild-type M. bovis BCG and of IL-12p40/IL-10 induced by M.
bovis BCG pimE capA to IL-12p40/IL-10 induced by wild-
type M. bovis BCG were calculated for LPS-primed MoDCs
from four different donors (one donor did not produce IL-10).
These ratios ranged from 0.66 to 1.33 (22 triplicate data sets),
with a median of 1.01. Hence, we concluded that the IL-12p40/
IL-10 ratios of the two mutant strains were identical to that of
the wild-type strain, meaning that the absence of PIM6, either
alone or in combination with missing mannose caps on LAM,
did not alter the IL-12p40/IL-10 balance.
DISCUSSION
In this study, we demonstrated that the degree of mannosy-
lation, in particular, the presence of (132)-linked mannosyl
residues in polar PIM6 (Fig. 1), determines the interaction of
PIMs with DC-SIGN. DC-SIGN showed a high affinity for
PIM6 but not for less mannosylated PIMs, including PIM4 (Fig.
2). Yet, a mutant strain deficient in the production of polar
PIMs bound as well to DC-SIGN as did wild-type M. bovis
BCG (Fig. 5). Even a double mutant which was also devoid of
mannose caps on LAM did not bind less to DC-SIGN and
DCs. Binding of the mutant strains could still be blocked by
mannan, indicating that additional DC-SIGN ligands were
present.
It has been suggested that mycobacteria target DC-SIGN
to escape immune surveillance (26, 69). However, studies
investigating single nucleotide polymorphisms in the pro-
moter region of DC-SIGN have shown a reduced risk of TB
associated with both downregulation (70) and upregulation
(7) of DC-SIGN expression or even no association with
susceptibility to TB at all (9, 29). A study with mice lacking
SIGNR1—one of the murine homologs of DC-SIGN—
showed that these mice had stronger T-helper 1 responses to
M. tuberculosis and a reduced level of IL-10 (72). However,
no differences in bacterial load and mouse survival rates
could be detected (72). In a recent publication on human
DC-SIGN transgenic mice, a decreased pathology and pro-
longed survival during mycobacterial infection have been
reported. In this case, no differences in IL-10 secretion
could be detected (64). It should be taken into account that
the murine DC-SIGN system is different from the human
one in both expression and specificity and it is not known yet
which homolog is functionally most similar to the human
DC-SIGN version (58, 60). Hence, many questions regard-
ing the functional consequences of the interaction between
mycobacteria and DC-SIGN still exist (51).
Mycobacterial strains that show a reduced binding to DC-
SIGN will help to elucidate the role of DC-SIGN in mycobac-
FIG. 6. Induction of IL-10 (A) and IL-12p40 (B) secretion in
MoDCs by M. bovis BCG. MoDCs were cocultured with mycobacteria
for 24 h in the absence or presence of LPS, after which cytokine
secretion was measured by ELISA. Shown are means of triplicates and
the standard deviations of one representative experiment (five were
conducted). IL-10 secretion by non-LPS-activated MoDCs upon infec-
tion with BCG was below the limit of detection (20 pg ml1). ***,
P 0.0005; **, P 0.005; *, P 0.05 (compared to wild-type M. bovis
BCG at equal MOIs).
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terial pathogenesis. In principle, such strains can be developed
by deleting the major DC-SIGN ligand(s) present. In contrast
to what has long been thought, deletion of the mannose cap on
LAM did not abrogate the DC-SIGN–mycobacterial interac-
tion (5). Polar PIMs, i.e., PIM5 and PIM6, have been proposed
before as possible ligands for DC-SIGN (67). Although it was
shown that the degree of PIM mannosylation did not deter-
mine its binding to DC-SIGN (67), we decided to reconsider
the case for two separate reasons. First, DC-SIGN shows an
unambiguous high affinity of for (132)-interlinked mannosyl
residues and this affinity increases with the number of manno-
syl residues present, suggesting that DC-SIGN, in theory,
should display an increased affinity toward higher-order PIMs
(20, 42), and second, previous studies on PIMs were only
performed with purified or synthetic compounds and not with
whole mycobacteria.
In two independent assay systems with (i) ELISA plates
coated with different species of PIMs and probing with DC-
SIGN-Fc and (ii) PIM-coated beads used in binding studies
with DC-SIGN expressing cells, we observed a clear difference
in the affinity of DC-SIGN for the individual species of PIMs
(Fig. 2); only PIM6 was recognized by DC-SIGN. Even at high
concentrations (10 g per well with ELISA) or at high bead-
to-cell ratios (100:1; data not shown), we did not detect signif-
icant binding of DC-SIGN to synPIM2, synPIM4, or natPIM1,2.
Whether the degree and nature of acylation of the PIMs
played a role in their binding to DC-SIGN was not directly
assessed. However, these data suggest that this is not important
because the synPIMs, which were all diacylated with identical
fatty acids and were single discrete species, displayed binding
properties similar to those of the analogous natPIMs, which
contained mixtures of mono- to tetra-acylated PIMs. More-
over, natPIM6 and synPIM6 both showed a high affinity for
DC-SIGN, indicating that differences in affinity are directly
related to the degree of mannosylation. Strikingly, our results
are different from those reported by Torrelles et al. (67). In
that study, it was demonstrated that all PIMs, irrespective of
their degree of mannosylation, showed similar binding to DC-
SIGN. We have no ready explanation for the difference in
outcome; however, we do note that the magnitude of the bind-
ing of PIMs to DC-SIGN reported in the study by Torrelles et
al. was very small for all of the species tested and thus lacked
specificity. Our data are more in agreement with a recent study
by Boonyarattanakalin and coworkers (12). This study on the
chemical synthesis of PIMs showed a high affinity of DC-SIGN
for the polar PIMs, i.e., PIM5 and PIM6, and low or no affinity
for the less mannosylated PIMs, i.e., PIM2 and PIM4, respec-
tively, in a fluorescence scanning assay of a PIM microarray.
The M. bovis BCG pimE and pimE capA mutant strains
were created to investigate the role of polar PIMs in the in-
teraction between DC-SIGN and whole mycobacteria. Al-
though polar PIMs have been reported to be essential for cell
wall integrity and mycobacterial growth (31), no differences in
growth between the mutant and parent strains were observed
(see Fig. S6 in the supplemental material), except for a higher
tendency of the mutant strains to clump in older cultures (1.5
weeks) at high optical densities at 600 nm (data not shown).
Interestingly, the M. bovis BCG pimE and pimE capA
mutant strains accumulated PIM4, a feature which was not
observed in wild-type M. bovis BCG. This confirms that in
wild-type M. bovis BCG, PIM4 is an intermediate in polar PIM
biosynthesis (28).
The M. bovis BCG pimE and pimE capA mutant strains
did not show apparent phenotypic changes other than the
altered production of PIM6 and the mannose caps on LAM.
Since DC-SIGN specifically bound PIM6 in vitro (Fig. 2), we
hypothesized that deletion of PIM6 may reduce mycobacterial
binding to cells expressing DC-SIGN. To test this, we first
compared the wild-type and mutant bacteria for binding to
MoDCs. The results indicated that both the M. bovis BCG
pimE and pimE capA mutant strains bound as well to
MoDCs as did the wild-type strain (Fig. 5A). To exclude the
possibility that other receptors on MoDCs masked a reduced
affinity of DC-SIGN for the mutant strains, binding of the
wild-type and mutant strains to Raji cells expressing DC-SIGN
was also assessed. Also in this case, no reduction and in some
cases even a small increase in the binding of the mutant strains
compared to that of the wild-type strain was observed (Fig.
5B). This latter finding could be due to a less hydrophobic cell
surface of the mutant strains, as was reported for an M. smeg-
matis pimE mutant (49), since the increased binding was also
observed for wild-type Raji cells, which do not express DC-
SIGN (see Fig. S3 in the supplemental material). Binding of
the mutant strains to MoDCs could still be blocked by mannan
(Fig. 5), as well as by DC-SIGN-blocking antibody AZN-D1
(see Fig. S4 in the supplemental material). Therefore, we con-
clude that the absence of PIM5 and PIM6 in the mutant strains
did not alter receptor usage for MoDCs: DC-SIGN was still
the major receptor.
Finally, wild-type M. bovis BCG and the pimE and pimE
capA mutant strains were assayed for the ability to induce
IL-12p40 and IL-10 secretion by MoDCs. The balance between
IL-10 and IL-12 is important for shaping the host immune
response, and alterations in it may thus influence the outcome
of mycobacterial infections (4, 37, 50). Binding to DC-SIGN
enhances the transcription of the IL-10 gene upon TLR sig-
naling (30). Furthermore, PIMs have been reported to sup-
press allergic airway disease, which is associated with increased
production of IL-10 (2, 63). However, PIM1 and PIM2 were
used in the latter two studies (2, 63) and IL-10 induction in this
case likely involves a different pathway (22). In our experi-
ments, in which LPS-primed MoDCs were cocultured with
wild-type M. bovis BCG or the pimE and pimE capA
mutant strains, no decrease in IL-10 secretion by MoDCs in-
cubated with the mutant strains compared to wild-type M.
bovis BCG was found (Fig. 6A). Instead, there was a tendency
toward higher cytokine (IL-10, IL-12p40, and IL-12p70) induc-
tion by the mutant strains compared to that by wild-type M.
bovis BCG (see Fig. S8 and S9 in the supplemental material).
However, because the mutant strains induced higher produc-
tion of both anti-inflammatory IL-10 and proinflammatory IL-
12p40, the increased cytokine production is probably not bio-
logically significant. Importantly, it should be noted that IL-10
induction by mycobacteria alone could not be detected. Only
after costimulation with LPS did M. bovis BCG induce the
secretion of IL-10. Since mycobacteria do not contain LPS,
although other TLR4 ligands may be present (18), it will be
important to investigate DC-SIGN-dependent IL-10 induction
also with other classes of TLR ligands (particularly TLR2).
In summary, we have shown that although DC-SIGN has a
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high affinity for PIM6, this glycolipid does not dictate the My-
cobacterium–DC-SIGN interaction. This finding demonstrates,
like our previous study (5), that the interaction of mycobacteria
with DC-SIGN is much more complex than initially antici-
pated. Furthermore, it demonstrates that studies with purified
compounds should be interpreted with great care. In addition,
our study shows that mycobacteria do not express one or two
but probably many more ligands for DC-SIGN. As shown in
Fig. 4 (lower right panel), DC-SIGN-Fc recognized, besides
ManLAM and PIM6, many additional bands (lane 4). These
bands most likely represent mannosylated proteins, which are
known to be expressed by mycobacteria (19). For at least the
45-kDa glycoprotein, it has been reported that the mannobiose
and mannotriose units present are all (132) linked and thus
reminiscent of the mannose cap on ManLAM (17). If these
proteins are indeed involved in the binding of mycobacteria to
DC-SIGN, creation of mutant strains displaying reduced bind-
ing will be a huge task to perform. It will therefore be of great
importance to evaluate the role of mannosylated proteins in
the binding of mycobacteria to DC-SIGN.
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